

17 February 2016

ASX Code: MXC

## Confirmations

The Company confirms the following:

1. there have been no material subsequent events to alter the Company's consolidated statement of financial position as detailed in section 6 of the Prospectus dated 18 December 2015 other than detailed in the Supplementary Prospectus dated 11 February 2016.
2. MGC Pharma (UK) Ltd, a subsidiary of MGC Pharmaceuticals Ltd, has completed the acquisition of MGC Pharmaceuticals d.o.o in Slovenia.
3. there are no legal, regulatory or contractual impediments to the Company undertaking the activities the subject of the commitments disclosed in the Prospectus, and in particular a statement setting out, to the satisfaction of ASX, that the directors have obtained an Australian legal opinion in respect of its proposed operations and are confident that there is no legal impediment (with reference to the Australian State and Commonwealth laws) to the Company's carrying out its proposed operations.
4. the Company is in compliance with the listing rules and in particular listing rule 3.1.

**-Ends-**